 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- || Clinical, Journal: Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. (Pubmed Central) - Jul 8, 2020
This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation.
- || methotrexate / Generic Mfg., CNTO6785 / J&J
Clinical, P2 data, Journal: CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study. (Pubmed Central) - Nov 19, 2019
This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation. CNTO6785 was well tolerated, but did not demonstrate clinical efficacy in patients with active RA with inadequate response to MTX.
- |||| CNTO6785 / J&J, Fontacea
Trial completion: A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jan 6, 2016
P2, N=187, Completed, Sponsor: Janssen Research & Development, LLC
CNTO6785 was well tolerated, but did not demonstrate clinical efficacy in patients with active RA with inadequate response to MTX. Active, not recruiting --> Completed
- |||| CNTO6785 / J&J, Fontacea
Trial completion: An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Aug 11, 2015
P2, N=257, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Completed
- ||| CNTO6785 / J&J, Fontacea
Enrollment closed: A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Apr 29, 2015
P2, N=187, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Recruiting --> Active, not recruiting
- || CNTO6785 / J&J, Fontacea
Trial primary completion date: An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jan 5, 2015
P2, N=250, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Jun 2015
- |||| CNTO6785 / J&J, Fontacea
Enrollment open: A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jan 8, 2014
P2, N=170, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- ||||| CNTO6785 / J&J, Fontacea
New P2 trial: A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Oct 17, 2013
P2, N=170, Recruiting, Sponsor: Janssen Research & Development, LLC
- ||||| CNTO6785 / J&J, Fontacea
New P2 trial: An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jul 24, 2013
P2, N=250, Recruiting, Sponsor: Janssen Research & Development, LLC
- | CNTO6785 / J&J, Fontacea
Trial completion: A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers (clinicaltrials.gov) - Jan 9, 2012
P1, N=32, Completed, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting Active, not recruiting --> Completed